| Top 50 Most Viewed Posts Last Month |
|---|
|
Today This Week Last Week This Month Last Month
|
| 1. Rosner: Short Interest Report As of Sat, Aug 3, '13 (4433) |
2. KenChowder: For what it's worth, Dr. Max Lataillade is not (3901)  (23) |
| 3. My69z: Dr. Palmer / Ascletis : *Gannex, a wholly owned (1914) (9) |
| 4. Jake2212: " Syneos Health has helped to develop or (1443) (24) |
| 5. ohm20: It looks like Leronlimab will compliment (1430) (25) |
| 6. My69z: Consider this: Dr. Lataillade hiring; Nov. 2023 (1307) (10) |
| 7. My69z: Gaudinski / GSK / VRC07-523LS: 2019 Pi on (1300) (6) |
| 8. mightycydy: Re: CYDY's new hire - Dr. Max Lataillade Video (1289) (8) |
| 9. riskreward007: Smart or not, she and army are both trying to (1271) (4) |
| 10. Albert364: Love International Group, Inc. (LOVV) is a (1257) |
| 11. My69z: She left L'oreal for GlaxoSmithKline in May 2010. (1227) (5) |
| 12. My69z: Max/GSK/FDA/Fostemsavir: Meeting Category: (1180) (18) |
| 13. armyseal: Reality is hard to come by for many they simply (1126) (3) |
| 14. ohm20: Leronlimab - Disease List (currently 90) (updated (1098) (28) |
| 15. Biolyfe: Board of directors. So to Jump Right In, I'll (1056) (23) |
| 16. Katangolo: Love seeing us partnering. Little CYDY is growing (1039) (12) |
| 17. BZE: Zero updates in 2023 on web archive but 5 updates (1003) (2) |
| 18. Jake2212: Perhaps TAK, not MRK, lies in LL's future. We all (994) (32) |
| 19. biloxiblues: I think everything hinges on what comes back from (885) (14) |
| 20. testuser: A Agilent Technologies AA Alcoa Inc. AAN Aaron's (868) |
| 21. jk1: $SNPW> Fox-ess's Global Partner, * Type in Global (867) (1) |
| 22. Katangolo: 700k shares were Rangebound by 0.02 cents since (826) (6) |
| 23. ohm20: If that's correct (and please correct me if I'm (819) (27) |
| 24. Plotinus: It would be of interest to see the protocol for (812) (25) |
| 25. USS JOHNSTON: The United States is the greatest nation on God's (807) (18) |
| 26. ohm20: fixed your post viewed as too crazy at the (799) (8) |
| 27. My69z: Did not realize GSK's R&D focus is the immune (792) (5) |
| 28. Evil Rabbit: This is off-topic and there are many many (774) (16) |
| 29. ohm20: Cytodyn doesn’t have enough $ resources to (754) (17) |
| 30. Smoking901: I found it very interesting, if you contacted the (748) (8) |
| 31. My69z: Started 2018 related to resevoir: Here, we (743) (3) |
| 32. dfwl28: Thanks ohm. Good news. This could eliminate most (738) (5) |
| 33. KenChowder: Great that 5000 girls and young women did not (724) (8) |
| 34. ohm20: would a Phase III that repeats the Phase II be (715) (13) |
| 35. biloxiblues: https://www.foxnews.com/media/rfk-jr-wants-clear- (714) (9) |
| 36. MGK_2: So, in the experiment, they took 4 monkeys (704) (14) |
| 37. dfwl28: https://www.globenewswire.com/news-release/2024/1 (698) (6) |
| 38. MJS719: From Reddit: More research driven use for (697) (14) |
| 39. chazzledazzle: I agree with you both. The Janet Woodcock email (694) (6) |
| 40. Plotinus: A couple of comments after attending the RECOVER (692) (24) |
| 41. Dloggold: What is humorous is you are trying to make that (692) |
| 42. KenChowder: I may not be reading the abstract right. Yes, (690) (13) |
| 43. Blindspot: Not the one dancing. From what other (689) |
| 44. MGK_2: Exactly cardamine. Most of the impurities have (689) (6) |
| 45. My69z: LL / CCL4: Jan. 2021. "Leronlimab blocks CCL5, (688) (6) |
| 46. Katangolo: Looking more and more likely that the PDL-1s are (686) (13) |
| 47. Shredbull23: Ok sparknut coming from the clown who would flip (686) (3) |
| 48. Figgs: Ever since I got my job as a lobbyist for Gilead (685) (6) |
| 49. Kanola: He was at the back of the Brain Line and got what (683) |
| 50. Drano: And that is exactly why this Pestell garbage has (681) (5) |
